Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents--a randomized, prospective, crossover, open clinical trial

Norbert Hermanns, Bernd Kulzer, Thomas Kohlmann, Stephan Jacob, Wolfgang Landgraf, Karlheinz Theobald, Thomas Haak, Norbert Hermanns, Bernd Kulzer, Thomas Kohlmann, Stephan Jacob, Wolfgang Landgraf, Karlheinz Theobald, Thomas Haak

Abstract

Background: Pharmacological and clinical differences between insulin glargine and NPH insulin may translate into differences in patient reported outcomes, but existing data are equivocal.

Methods: In this 48-week, open-label, randomized, multi-center, crossover phase IV trial, insulin naïve type 2 diabetes patients with blood glucose not at target on oral hypoglycemic agents had basal insulin added to their treatment regimen. A total of 343 patients were randomized to either receive insulin glargine (n = 176; sequence A) or neutral protamine Hagedorn (NPH) insulin (n = 167; sequence B) in period 1 (weeks 1-24) and vice versa in period 2 (weeks 25-48). The primary objective was to assess patient reported outcomes using a composite Diabetes Related Quality of Life (DRQoL) score based on an unweighted Insulin Treatment Experience Questionnaire (ITEQ) score, a Problem Areas in Diabetes (PAID) questionnaire score, and the mental health score in the Short Form (SF)-12® Health Survey, analyzed by analysis of covariance (ANCOVA).

Results: Patients (mean age 62.3 ± 9.0; 39.5 % female) had a mean diabetes duration of 9.6 ± 5.9 years, a mean baseline HbA1c of 8.15 ± 0.72 %, and a mean fasting blood glucose (FBG) level of 9.37 ± 2.19 mmol/L. A total of 229 patients were available for primary endpoint evaluation (modified intention to treat population). Combining all data from both periods for each insulin treatment, on a 0-100 scale, the mean DRQoL score was 69.6 (±9.04) with insulin glargine and 70.0 (±9.40) with NPH insulin. Neither an effect of treatment with insulin glargine vs NPH insulin (p = 0.31) nor a period effect (p = 0.96), nor a sequence effect (p = 0.76) was observed using ANCOVA.

Conclusions: The results show that in a patient population with sub-optimal glycemic control at baseline, and a low target achievement rate together with a low rate of hypoglycemia, differences in the patient reported outcomes evaluated in this study were negligible between insulin glargine and NPH insulin.

Trial registration: Clinicaltrials.gov identifier: NCT00941369.

Figures

Fig. 1
Fig. 1
Study design. OAD, oral antidiabetic drugs / oral hypoglycemic agents corresponding to a maximum of 2 drugs out of metformin, sulfonylurea or a DPP-IV inhibitor; NPH, neutral protamine Hagedorn
Fig. 2
Fig. 2
Patient disposition. No further data are available for patients not getting randomized
Fig. 3
Fig. 3
7-point blood glucose profile (ITT). Meaurements: 1-before breakfast, 2-2 h after breakfast, 3-before lunch, 4-2 h after lunch, 5-before dinner, 7-before sleeping. Source: bgprofcurve.sas[SVN:20879] Date Extract: 08FEB2013 Table Generation: 10JUNE2013 15:21

References

    1. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–31. doi: 10.7326/0003-4819-141-6-200409210-00007.
    1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical research ed) 2000;321(7258):405–12. doi: 10.1136/bmj.321.7258.405.
    1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Jama. 1999;281(21):2005–12. doi: 10.1001/jama.281.21.2005.
    1. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28(2):254–9. doi: 10.2337/diacare.28.2.254.
    1. Yki-Jarvinen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2002;18(Suppl 3):S77–81. doi: 10.1002/dmrr.304.
    1. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23(5):644–9. doi: 10.2337/diacare.23.5.644.
    1. Duckworth W, Davis SN. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complicat. 2007;21(3):196–204. doi: 10.1016/j.jdiacomp.2007.01.001.
    1. Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of medical research. 2006;37(4):495–501. doi: 10.1016/j.arcmed.2005.10.015.
    1. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28(4):950–5. doi: 10.2337/diacare.28.4.950.
    1. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23(8):1130–6. doi: 10.2337/diacare.23.8.1130.
    1. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442–51. doi: 10.1007/s00125-005-0132-0.
    1. Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes educ. 2008;34(3):511–7. doi: 10.1177/0145721708317869.
    1. Edelman S, Pettus J. Challenges associated with insulin therapy in type 2 diabetes mellitus. Am J Med. 2014;127(10 Suppl):S11–6. doi: 10.1016/j.amjmed.2014.07.003.
    1. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543–5. doi: 10.2337/diacare.28.10.2543.
    1. Witthaus E, Stewart J, Bradley C. Improved psychological outcomes after initiation of insulin treatment in patients with type II diabetes. Diabetologia. 2000;43(Suppl. 1):Abstract 205.
    1. Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T. Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany. Dtsch Med Wochenschr. 2009;134(23):1207–13. doi: 10.1055/s-0029-1222595.
    1. American Diabetes A. Standards of medical care in diabetes–2008. Diabetes Care. 2008;31(Suppl 1):S12–54. doi: 10.2337/dc08-S012.
    1. Moock J, Hessel F, Ziegeler D, Kubiak T, Kohlmann T. Development and Testing of the Insulin Treatment Experience Questionnaire (ITEQ) The patient. 2010;3(1):45–58. doi: 10.2165/11319510-000000000-00000.
    1. Welch GW, Jacobson AM, Polonsky WH. The Problem Areas in Diabetes Scale. An evaluation of its clinical utility. Diabetes care. 1997;20(5):760–6. doi: 10.2337/diacare.20.5.760.
    1. Hermanns N, Kulzer B, Krichbaum M, Kubiak T, Haak T. How to screen for depression and emotional problems in patients with diabetes: comparison of screening characteristics of depression questionnaires, measurement of diabetes-specific emotional problems and standard clinical assessment. Diabetologia. 2006;49(3):469–77. doi: 10.1007/s00125-005-0094-2.
    1. Ware J, Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33. doi: 10.1097/00005650-199603000-00003.
    1. EuroQol G. EuroQol–a new facility for the measurement of health-related quality of life. Health policy. 1990;16(3):199–208. doi: 10.1016/0168-8510(90)90421-9.
    1. Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. The European journal of health economics : HEPAC : health economics in prevention and care. 2005;6(2):124–30. doi: 10.1007/s10198-004-0264-z.
    1. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2003;35(3):189–96. doi: 10.1055/s-2003-39080.
    1. Bradley C, Plowright R, Stewart J, Valentine J, Witthaus E. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Health Qual Life Outcomes. 2007;5:57. doi: 10.1186/1477-7525-5-57.
    1. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine Study I The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–6. doi: 10.2337/diacare.26.11.3080.
    1. Green AJ, Fox KM, Grandy S. Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2012;96(3):313–8. doi: 10.1016/j.diabres.2012.01.002.
    1. Williams SA, Shi L, Brenneman SK, Johnson JC, Wegner JC, Fonseca V. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complicat. 2012;26(5):399–406. doi: 10.1016/j.jdiacomp.2012.05.002.
    1. Lopez-Alvarenga JC, Aguilar-Salinas CA, Velasco-Perez ML, Arita-Melzer O, Guillen LE, Wong B, et al. Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus. Diabetes Obes Metab. 1999;1(1):29–35. doi: 10.1046/j.1463-1326.1999.00007.x.
    1. Panahloo A, Mohamed-Ali V, Andres C, Denver AE, Yudkin JS. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes. Metab Clin Exp. 1998;47(6):637–43. doi: 10.1016/S0026-0495(98)90023-3.
    1. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240–5. doi: 10.2337/dc09-1348.
    1. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673–9. doi: 10.2337/diacare.28.11.2673.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel